{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:31Z","timestamp":1791849631792,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN 156064"],"award-info":[{"award-number":["FRN 156064"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jcjd.2021.12.005","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T12:06:00Z","timestamp":1640865960000},"page":"392-403.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score\u2013matched Population-based Cohort Study"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-0442","authenticated-orcid":false,"given":"Wajd","family":"Alkabbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Zongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasjeet K.","family":"Minhas-Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean T.","family":"Eurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-3628","authenticated-orcid":false,"given":"Baiju R.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-9528","authenticated-orcid":false,"given":"Mhd Wasem","family":"Alsabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-8721","authenticated-orcid":false,"given":"John-Michael","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2021.12.005_bib1","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: Weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jcjd.2021.12.005_bib2","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib3","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","article-title":"Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria","volume":"103","author":"Geerlings","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2021.12.005_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jcjd.2021.12.005_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcjd.2021.12.005_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/dom.13959","article-title":"A\u00a0hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection","volume":"22","author":"Fralick","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2021.12.005_bib15","first-page":"129","article-title":"Urinary tract infections in patients with type 2 diabetes mellitus: Review of prevalence, diagnosis, and management","volume":"8","author":"Nitzan","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.jcjd.2021.12.005_bib16","first-page":"1409","article-title":"A\u00a0payer perspective of the costs of urinary tract and skin and soft tissue infections in adults with diabetes and the relationship to oral antidiabetic medication nonadherence","volume":"25","author":"Davis-Ajami","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jcjd.2021.12.005_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jcjd.2021.12.005_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes---a systematic review","volume":"140","author":"R\u00e5dholm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2021.12.005_bib19","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjd.2021.12.005_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/2042098621989134","article-title":"Adverse events associated with sodium glucose co-transporter 2 inhibitors: An overview of quantitative systematic reviews","volume":"12","author":"Pelletier","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jcjd.2021.12.005_bib21","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.9778\/cmajo.20180111","article-title":"Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: A systematic review and network meta-analysis of randomized controlled trials","volume":"6","author":"Donnan","year":"2018","journal-title":"CMAJ Open"},{"key":"10.1016\/j.jcjd.2021.12.005_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib23","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jcjd.2021.12.005_bib24","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/dom.14082","article-title":"Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study","volume":"22","author":"Fisher","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2021.12.005_bib25","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2021.12.005_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/2042098621997703","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes","volume":"12","author":"Varshney","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jcjd.2021.12.005_bib27","article-title":"Long-term effectiveness and safety of SGLT2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus","volume":"2019","author":"Mirabelli","year":"2019","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jcjd.2021.12.005_bib28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/dom.14261","article-title":"Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study","volume":"23","author":"Han","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2021.12.005_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcjd.2021.12.005_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: A systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jcjd.2021.12.005_bib31","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1592\/phco.23.5.686.32205","article-title":"Validity of the general practice research database","volume":"23","author":"Jick","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcjd.2021.12.005_bib32","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.3399\/bjgp10X483562","article-title":"Validity of diagnostic coding within the General Practice Research Database: A systematic review","volume":"60","author":"Khan","year":"2010","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.jcjd.2021.12.005_bib33","first-page":"684","article-title":"Completeness and usability of ethnicity data in UK-based primary care and hospital databases","volume":"36","author":"Mathur","year":"2014","journal-title":"J\u00a0Public Health (Oxf)"},{"key":"10.1016\/j.jcjd.2021.12.005_bib34","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.jcjd.2021.12.005_bib35","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A\u00a0comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jcjd.2021.12.005_bib37","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of Martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.jcjd.2021.12.005_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"10.1016\/j.jcjd.2021.12.005_bib40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: A tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcjd.2021.12.005_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<13::AID-SIM279>3.0.CO;2-5","article-title":"Survival analysis for recurrent event data: An application to childhood infectious diseases","volume":"19","author":"Kelly","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/M13-2886","article-title":"Random-effects meta-analysis of inconsistent effects: A time for change","volume":"160","author":"Cornell","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib43","unstructured":"Deeks JJ, Higgins JPT, Altman DG, editors. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Updated February 2021. www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.jcjd.2021.12.005_bib44","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jcjd.2021.12.005_bib45","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jdiacomp.2017.07.018","article-title":"Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes","volume":"31","author":"Nichols","year":"2017","journal-title":"J\u00a0Diabetes Complic"},{"key":"10.1016\/j.jcjd.2021.12.005_bib46","first-page":"1288","article-title":"Urologic diseases in America project: Trends in resource use for urinary tract infections in men","volume":"173","author":"Griebling","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.jcjd.2021.12.005_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: Pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jcjd.2021.12.005_bib48","first-page":"A47","article-title":"Discontinuation of sodium-glucose co-transporter 2 inhibitors due to recurrent genitourinary infections","volume":"25","author":"Lorenzo","year":"2018","journal-title":"Eur J Hosp Pharm"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149926712100472X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S149926712100472X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:37:44Z","timestamp":1761493064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S149926712100472X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S149926712100472X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2021.12.005","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score\u2013matched Population-based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2021.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published on behalf of the Canadian Diabetes Association.","name":"copyright","label":"Copyright"}]}}